JPRN-UMIN000033752已完成3 期
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects - ET002J
Medical Corporation Tokushukai Shonanfujisawa Tokushukai Hospital0 个研究点目标入组 10 人开始时间: 2018年9月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects with unstable cardiac status 2. Subjects exhibiting any behaviors consistent with ethanol or substance abuse 3. Severe hypertension 4. Subjects with standard contraindications for MR imaging. 5. Known intolerance or allergies to the MRI contrast agent. 6. Patient with severely impaired renal function or who is on dialysis 7. History of abnormal bleeding or coagulopathy. 8. Receiving anticoagulant or antiplatelet therapy within one week, or drugs 9. Active or suspected acute or chronic uncontrolled infection 10. History of immunocompromise. 11. History of intracranial hemorrhage 12. Cerebrovascular disease 13. Subjects with uncontrolled symptoms and signs of increased intracranial pressure. 14. Individuals who are not able or willing to tolerate the required prolonged stationary supine position. 15. Are participating or have participated in another clinical trial 16. Significant claustrophobia 17. Subjects unable to communicate. 18. Presence of any other neurodegenerative disease such as Parkinson plus syndromes 19. Anyone suspected to have the diagnosis of idiopathic Parkinson's disease. 20. Presence of significant cognitive impairment 21. Subjects with life threatening systemic disease 22. Subjects with a history of seizures 23. Subjects with presence or history of psychosis or active mood disorders will be excluded. 24. Subjects with risk factors for intraoperative or postoperative bleeding. 25. Subjects with brain tumors 26. Pregnancy or lactation. 27. Legal incapacity or limited legal capacity. 28. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia 29. Subjects who have been administered botulinum toxins 30. Subjects who have an Overall Skull Density Ratio of 0.3 or less as calculated from the screening CT. 31. Any illness that in the investigator's opinion preclude participation in this study.
研究者
相似试验
已完成
不适用
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor SubjectsEssential TremorJPRN-UMIN000023639Departments of Neurology and Neurosurgery, Hokuto Hospital10
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor SubjectsMedication Refractory Essential TremorJPRN-UMIN000019498Department of Neurosurgery, Osaka University School of Medicine10
已完成
不适用
Safety and effectiveness of TOPS™ SystemSingle Level Lumbar Spine Stenosis (with up to a grade 1 spondylolisthesis)SurgeryISRCTN47205504Premia Spine Ltd (Israel)10
招募中
4 期
The effect and safety of the drug Acyclovir in patients of Pityriasis rosea (a widespread red and scaly lesion following infection or drug intake)CTRI/2013/12/004240Institutional Medical College Kolkata24
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2018-003866-14-ESApexigen, Inc.174